<code id='2C69654810'></code><style id='2C69654810'></style>
    • <acronym id='2C69654810'></acronym>
      <center id='2C69654810'><center id='2C69654810'><tfoot id='2C69654810'></tfoot></center><abbr id='2C69654810'><dir id='2C69654810'><tfoot id='2C69654810'></tfoot><noframes id='2C69654810'>

    • <optgroup id='2C69654810'><strike id='2C69654810'><sup id='2C69654810'></sup></strike><code id='2C69654810'></code></optgroup>
        1. <b id='2C69654810'><label id='2C69654810'><select id='2C69654810'><dt id='2C69654810'><span id='2C69654810'></span></dt></select></label></b><u id='2C69654810'></u>
          <i id='2C69654810'><strike id='2C69654810'><tt id='2C69654810'><pre id='2C69654810'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:comprehensive    - browse:6
          Alnylam headquarters
          Kristoffer Tripplaar/Sipa USA/AP

          Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

          Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

          advertisement

          The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          knowledge